FDA Brief

Warning letters Drugs

FDA warning letter to

Zhao Qing Longda Biotechnology Co. Ltd.

High riskIssued Sep 18, 2023Posted Sep 26, 2023Center for Drug Evaluation and Research | CDER

FDA says Zhao Qing Longda Biotechnology refused records access for OTC drugs, including children’s toothpaste, and placed its drugs on import alert.

What happened

FDA reviewed import records showing shipments into the U.S. that named Zhao Qing Longda Biotechnology as manufacturer of OTC drugs, including children’s toothpaste, with ingredients that can be substituted with diethylene glycol (DEG) or ethylene glycol (EG). FDA sent a records request on March 17, 2023, and follow-ups on April 6 and April 18; the firm did not answer, and on April 19 said it was “not prepared to allow the FDA to audit and inspect” the firm. A later written request to the registered address had a delivery failure, and FDA placed all the firm’s drugs on Import Alert 66-79 on August 29, 2023.

What FDA found

  1. The firm did not answer FDA’s March 17, 2023 electronic request for records and other information about its drug manufacturing.

    section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)
  2. The firm did not answer FDA’s second and third email requests sent April 6 and April 18, 2023.

    section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)
  3. On April 19, 2023, the firm responded that it was “not prepared to allow the FDA to audit and inspect” the firm.

    section 301(e) of the FD&C Act, 21 U.S.C. 331(e)
  4. Refusing to permit access to or copying of records required by section 704(a) is a prohibited act.

    section 301(e) of the FD&C Act, 21 U.S.C. 331(e)
  5. FDA said it has no indication of the level of quality assurance for drugs registered as manufactured at the facility because the firm failed to respond to records requests.

What FDA wants

Respond in writing within 15 working days; you may provide information for FDA to consider and/or request an FDA inspection, and send the electronic reply to the listed FDA address with FEI #3014354419 and ATTN: Matthew R. Dionne.

Who should pay attention

  • U.S. brands and distributors buying OTC drugs or children’s toothpaste from Chinese manufacturers
  • companies relying on foreign contract manufacturers for drug products
  • regulatory teams handling FDA import alerts and supplier records requests

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Zenzi Pharmaceutical Industries Pvt. Ltd.

    Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.

    High risk
  3. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  4. Gulf States International, Inc.

    Gulf States International refused FDA requests for OTC drug manufacturing records, FDA says.

    Medium